[Psychiatry].
The main innovation of the year 2004 was the introduction of a new, second-generation antipsychotic drug with a new mechanism of action (partial dopamine agonist), encouraging first clinical results, and an advantageous clinical tolerance profile. Additionally, three new galenic forms are presented: an oral, extended-release form of methylphenidate that could be useful in the treatment of attention-deficit/hyperactivity disorders; an intramuscular depot form of a second-generation antipsychotic drug (risperidone) with the advantage of improving adherence; and an intramuscular form of a second generation antipsychotic (olanzapine) that is valuable in emergency situations. Finally, we will briefly give an update on the advantages of lamotrigine in bipolar depression.
Bryois
C
C
Hôpital de Prangins, Secteur de psychiatrie ouest du canton de Vaud. christian.bryois@inst.hospvd.ch
Nanzer
N
N
Eliez
S
S
Etter
M
M
Aubry
J M
JM
Bertschy
G
G
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D006801:Humans; D000077213:Lamotrigine; D001523:Mental Disorders / Q000188:drug therapy*; D008774:Methylphenidate / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D018967:Risperidone / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D014227:Triazines; D008774:Methylphenidate; D000068180:Aripiprazole; D018967:Risperidone; D000077213:Lamotrigine